Bio-Rad Labs (NYSE: BIO) reported Q1 EPS of $2.54, $0.74 better than the analyst estimate of $1.80. Revenue for the quarter came in at $585.4 million versus the consensus estimate of $573.22 million.

Updated Full-Year 2025 Financial Outlook

Bio-Rad is updating its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue to range from approximately a 1.0 percent decline to 1.5 percent growth versus its prior revenue growth estimate of approximately 1.5 to 3.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent compared to its prior expectation of approximately 13.0 to 13.5 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.